Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Parikh, Ravi H.; Seliger, Stephen L.; Christenson, Robert H.; Gottdiener, John S.; Psaty, Bruce M.; deFilippi, Christopher R.

doi:10.1161/jaha.115.003188

Cited by 75 publications

(63 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was true for both patients with dyspnea as well as those with acute heart failure[36]. In a recent study, Parikh et al[37] studied population of community-dwelling older individuals enrolled in the Cardiovascular Health Study. They found that soluble ST2 levels were significantly associated with incident heart failure, cardiovascular death and that greater ST2 level was continuously associated with increasing hazard for cardiovascular death[37].…”

Section: St2mentioning

confidence: 99%

“…In a recent study, Parikh et al[37] studied population of community-dwelling older individuals enrolled in the Cardiovascular Health Study. They found that soluble ST2 levels were significantly associated with incident heart failure, cardiovascular death and that greater ST2 level was continuously associated with increasing hazard for cardiovascular death[37]. Various studies have documented the incremental value of addition of ST2 to pre-existing predictive models of heart failure[37,38].…”

Section: St2mentioning

confidence: 99%

“…They found that soluble ST2 levels were significantly associated with incident heart failure, cardiovascular death and that greater ST2 level was continuously associated with increasing hazard for cardiovascular death[37]. Various studies have documented the incremental value of addition of ST2 to pre-existing predictive models of heart failure[37,38]. Accumulation of these data have led the ACC/AHA guidelines to recommend ST2 measurement for additive risk stratification in patients with acute or chronic ambulatory heart failure[3].…”

Section: St2mentioning

confidence: 99%

See 2 more Smart Citations

Cardiac biomarkers in pediatric heart disease: A state of art review

Fernandes¹,

Maher²,

Deshpande³

2016

WJC

View full text Add to dashboard Cite

Every year there are more than 11000 hospitalizations related to heart failure in children resulting in significant morbidity and mortality. Over the last two decades, our understanding, diagnosis and management of pediatric heart failure is evolving but our ability to prognosticate outcomes in pediatric heart acute heart failure is extremely limited due to lack of data. In adult heart failure patients, the role of cardiac biomarkers has exponentially increased over the last two decades. Current guidelines for management of heart failure emphasize the role of cardiac biomarkers in diagnosis, management and prognostication of heart failure. It is also noteworthy that these biomarkers reflect important biological processes that also open up the possibility of therapeutic targets. There is however, a significant gap present in the pediatric population with regards to biomarkers in pediatric heart failure. Here, we seek to review available data regarding cardiac biomarkers in the pediatric population and also explore some of the emerging biomarkers from adult literature that may be pertinent to pediatric heart failure.

show abstract

Section: St2mentioning

confidence: 99%

Section: St2mentioning

confidence: 99%

Section: St2mentioning

confidence: 99%

See 1 more Smart Citation

Cardiac biomarkers in pediatric heart disease: A state of art review

Fernandes¹,

Maher²,

Deshpande³

2016

WJC

View full text Add to dashboard Cite

show abstract

“…sST2 level was found to be a useful biomarker of non‐response to GVHD therapy and improved risk stratification according to clinical grade . Meanwhile, baseline serum sST2 had good predictive value for heart failure and myocardial infarction of all subtypes and cardiovascular death in a large community‐dwelling population. These findings support our finding that elevated baseline sST2 level is associated with poor prognosis in ESRD patients who experience PDF.…”

Section: Discussionmentioning

confidence: 97%

ST2 blockade mitigates peritoneal fibrosis induced by TGF‐β and high glucose

Kim

Lee

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Peritoneal fibrosis (PF) is an intractable complication of peritoneal dialysis (PD) that leads to peritoneal membrane failure. This study investigated the role of suppression of tumorigenicity (ST)2 in PF using patient samples along with mouse and cell‐based models. Baseline dialysate soluble (s)ST2 level in patients measured 1 month after PD initiation was 2063.4 ± 2457.8 pg/mL; patients who switched to haemodialysis had elevated sST2 levels in peritoneal effluent (1576.2 ± 199.9 pg/mL, P = .03), which was associated with PD failure (P = .04). Baseline sST2 showed good performance in predicting PD failure (area under the receiver operating characteristic curve = 0.780, P = .001). In mice with chlorhexidine gluconate‐induced PF, ST2 was expressed in fibroblasts and mesothelial cells within submesothelial zones. In primary cultured human peritoneal mesothelial cells (HPMCs), transforming growth factor‐β treatment increased ST2, fibronectin, β‐galactosidase and Snail protein levels and decreased E‐cadherin level. Anti‐ST2 antibody administration reversed the up‐regulation of ST2 and fibronectin expression; it also reduced fibrosis induced by high glucose (100 mmol/L) in HPMCs. Thus, high ST2 level in dialysate is a marker for fibrosis and inflammation during peritoneal injury, and blocking ST2 may be an effective therapeutic strategy for renal preservation.

show abstract

“…Much work has also been conducted to establish associations between ST2 levels and clinical outcomes before and after cardiovascular procedures in specific populations 47, 48, 49, 50. The individual and combined predictive power of these 3 biomarkers, in addition to boost in predictive ability they have provided to existing preoperative models of mortality and risk in many cardiovascular conditions and procedures, merited their congruent consideration in a multi‐marker model aimed at preoperatively predicting in‐hospital mortality in patients after CABG 51, 52, 53…”

Section: Discussionmentioning

confidence: 99%

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery

Polineni

Parker

Alam

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundCurrent preoperative models use clinical risk factors alone in estimating risk of in‐hospital mortality following cardiac surgery. However, novel biomarkers now exist to potentially improve preoperative prediction models. An assessment of Galectin‐3, N‐terminal pro b‐type natriuretic peptide (NT‐ProBNP), and soluble ST2 to improve the predictive ability of an existing prediction model of in‐hospital mortality may improve our capacity to risk‐stratify patients before surgery.Methods and ResultsWe measured preoperative biomarkers in the NNECDSG (Northern New England Cardiovascular Disease Study Group), a prospective cohort of 1554 patients undergoing coronary artery bypass graft surgery. Exposures of interest were preoperative levels of galectin‐3, NT‐ProBNP, and ST2. In‐hospital mortality and adverse events occurring after coronary artery bypass graft were the outcomes. After adjustment, NT‐ProBNP and ST2 showed a statistically significant association with both their median and third tercile categories with NT‐ProBNP odds ratios of 2.89 (95% confidence interval [CI]: 1.04–8.05) and 5.43 (95% CI: 1.21–24.44) and ST2 odds ratios of 3.96 (95% CI: 1.60–9.82) and 3.21 (95% CI: 1.17–8.80), respectively. The model receiver operating characteristic score of the base prediction model (0.80 [95% CI: 0.72–0.89]) varied significantly from the new multi‐marker model (0.85 [95% CI: 0.79–0.91]). Compared with the Northern New England (NNE) model alone, the full prediction model with biomarkers NT‐proBNP and ST2 shows significant improvement in model classification of in‐hospital mortality.ConclusionsThis study demonstrates a significant improvement of preoperative prediction of in‐hospital mortality in patients undergoing coronary artery bypass graft and suggests that biomarkers can be used to identify patients at higher risk.

show abstract

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Cited by 75 publications

References 54 publications

Cardiac biomarkers in pediatric heart disease: A state of art review

Cardiac biomarkers in pediatric heart disease: A state of art review

ST2 blockade mitigates peritoneal fibrosis induced by TGF‐β and high glucose

Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin‐3, and NT‐ProBNP Before Cardiac Surgery

Contact Info

Product

Resources

About